Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Chemotherapy resistance is a major challenge in solid tumor treatment, necessitating novel therapeutic strategies.
• The p53 protein, frequently mutated in cancer, is a critical target, but p53-targeted drugs have faced clinical limitations.
• Current therapies often focus narrowly on p53 inactivation, neglecting broader network effects and cancer cell adaptation.

Purpose of the Study:

• To review the complexities of p53 signaling in cancer that impede drug development.
• To explore emerging gene therapy approaches targeting the p53 network and associated cellular dysfunction.
• To discuss current therapeutics with promising preclinical and clinical outcomes for p53-targeted cancer treatment.

Main Methods:

• Literature review of p53 signaling pathways in cancer.
• Analysis of current therapeutic strategies targeting p53 and its network.
• Evaluation of preclinical and clinical data for novel p53-targeting agents and gene therapies.

Main Results:

• p53 network dysregulation presents significant challenges for conventional p53-targeted drugs.
• Gene therapy approaches demonstrate potential for addressing cancer cell adaptation and p53 network dysfunction.
• Several novel therapeutics show promise in preclinical and early clinical studies.

Conclusions:

• Understanding p53 network complexities is crucial for developing effective cancer therapies.
• Targeting the p53 network, particularly through gene therapy, represents a promising avenue for overcoming treatment resistance.
• Emerging therapies offer hope for improved clinical responses in p53-mutated cancers.